{# max-image-preview:large is what makes an article eligible for the big-image card in Google Discover — without it Google may only show a thumbnail. #} {# ── Google Preferred Sources ──────────────────────────────────────────── Readers who mark us as a preferred source get our fresh articles prioritised in Top Stories, Discover and Google News. Only domain- and subdomain-level sites are eligible — blog.alfafinder.com qualifies, a /news/ subdirectory would not. #}

Kwality Pharmaceuticals — Latest News

Every announcement Kwality Pharmaceuticals has filed with the exchanges that we have reported, newest first. Each story links the original filing.

NSE: KPL BSE: 539997 Pharmaceuticals & Biotechnology 2 stories

Price

₹3308.05

Market Cap

₹3,432.50 Cr

Revenue TTM

₹553.96

P/E (TTM)

42.35×

Sector 45.79×

Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.

Earning Call · 2
Earning Call

Kwality Pharmaceuticals Targets ₹700 Crore Revenue in FY27 Following Guidance Revision

Kwality Pharmaceuticals revises FY27 revenue target to ₹700Cr+ and eyes ₹1,500Cr by FY30. Highlights include biosimilar expansion and 26-27% EBITDA m…
Earning Call

Kwality Pharmaceuticals Q1FY27: Revenue Surges 45% as FY27 Guidance Raised to ₹700 Cr+

Kwality Pharmaceuticals reports 45.7% YoY revenue growth in Q1FY27 to ₹162.4 Cr. Management raises FY27 revenue guidance to ₹700+ Cr on strong export…

Track Kwality Pharmaceuticals in real time

ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Kwality Pharmaceuticals files something material.

Start Free — 15-day trial
{# ── Promo popup — fires 5s after first page load per session. NEVER fires for visitors arriving from a search engine: a full-viewport overlay on a news article is an intrusive interstitial, and Google News policy is explicit that promotional material must not exceed the content. Direct, social and referral traffic still sees it. ─────────── #}